期刊
AMERICAN JOURNAL OF PATHOLOGY
卷 177, 期 2, 页码 1004-1016出版社
ELSEVIER SCIENCE INC
DOI: 10.2353/ajpath.2010.090703
关键词
-
类别
资金
- National Institutes of Health [CA69184]
- Swiss National Fund [3100A0-108207]
- Austrian Science Foundation [S9408-B11]
- Cancer League Zurich, Oncosuisse
- Commission of the European Communities [LSHC-CT-2005-518178]
The membrane glycoprotein podoplanin is expressed by several types of human cancers and might be associated with their malignant progression. Its exact biological function and molecular targets are unclear, however. Here, we assessed the relevance of tumor cell expression of podoplanin in cancer metastasis to lymph nodes, using a human MCF7 breast carcinoma xenograft model. We found that podoplanin expression promoted tumor cell motility in vitro and, unexpectedly, increased tumor lymphangiogenesis and metastasis to regional lymph nodes in vivo, without promoting primary tumor growth. Importantly, high cancer cell expression levels of podoplanin correlated with lymph node metastasis and reduced survival times in a large cohort of 252 oral squamous cell carcinoma patients. Based on comparative transcriptional profiling of tumor xenografts, we identified endothelin-1, villin-1, and tenascin-C as potential mediators of podoplanin-induced tumor lymphangiogenesis and metastasis. These unexpected findings identify a novel mechanism of tumor lymphangiogenesis and metastasis induced by cancer cell expression of podoplanin, suggesting that reagents designed to interfere with podoplanin function might be developed as therapeutics for patients with advanced cancer. (Am J Pathol 2010,177:1004-1016 DOI: 10.2353/ajpath.2010.090703)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据